Evidence map›Paper›PMID 35092562›Full record

ArticleMolecular biology reports2022

Anti-hyperglycemic effects of Eryngium billardierei F. Delaroche extract on insulin-resistance HepG2 cells in vitro.

Fatemeh Kheirollahzadeh, Elahe Eftekhari, Marzieh Ghollasi, Payam Behzadi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Host insulin resistance caused byFrontiers in cellular and infection microbiology · 2023
    Pooled it
  2. Article
  3. Article
  4. Palmitate-induced downregulation of lipocalin prostaglandin DMolecular and cellular endocrinology · 2025
    Article
  5. Article
  6. In vitro evaluation of milk incorporated withFood science & nutrition · 2024
    Article
  7. Experimental Approaches to Diabetes Mellitus.The Eurasian journal of medicine · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fatemeh KheirollahzadehDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Elahe EftekhariDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Marzieh GhollasiDepartment of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. ghollasi@khu.ac.ir.
Payam BehzadiDepartment of Microbiology, College of Basic Sciences, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran. behzadipayam@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInsulin resistance as a major problem is associated with type 2 diabetes mellitus. This study investigated the effect of Eryngium billardierei on insulin-resistance induced HepG2 cells. METHODS AND

resultsMTT method was used to evaluate the viability of HepG2 cells treated with various doses of E. billardierei extract. An insulin-resistance model was established in HepG2 cells. Next, MTT assay and Acridine orange staining were performed to investigate the viability of cells in the vicinity of different concentrations of insulin, pioglitazone, and E. billardierei extract in an insulin-resistance media. The glucose uptake test was performed to select the optimal insulin concentration. Expression levels of IR, G6Pase, and PEPCK genes were assessed by real-time RT-PCR. According to obtained data, E. billardierei at concentrations of 0.5 and 1 mg/mL show no toxicity on cells. Furthermore, based on MTT assay and glucose uptake test 10

conclusionsThe obtained data indicated that 1 mg/mL E. billardierei might have an anti-insulin resistance effect on insulin-resistance HepG2 cells in vitro and could be a promising candidate with anti-hyperglycemic properties for diabetes treatments.

Indexed as

Diabetes Mellitus, Type 2EryngiumInsulin ResistanceGlucoseHep G2 CellsHumansHypoglycemic AgentsInsulinPlant ExtractsGlucoseHypoglycemic AgentsInsulinPlant ExtractsEryngium billardiereiGlucose metabolismHepG2 cellsInsulin resistanceType 2 diabetes mellitus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.